Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SF2a-TT15 + alum
- Development stage
- Unknown
- Lead developer
- Institut Pasteur
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
SF2a-TT15 + alum is a **synthetic glycan-based conjugate vaccine candidate** designed to prevent infection by *Shigella flexneri* 2a, a major cause of shigellosis. The vaccine consists of a chemically synthesized pentadecasaccharide (15-mer) oligosaccharide that mimics the O-antigen of *S. flexneri* 2a, covalently conjugated to tetanus toxoid (TT) via a thiol-maleimide linker. The vaccine is formulated with aluminum hydroxide (alum; trade name Alhydrogel) as an adjuvant to enhance immunogenicity. Preclinical and phase 1 human studies demonstrated that the vaccine is strongly immunogenic, safe, and induces functional bactericidal antibodies against a wide range of circulating SF2a strains. The addition of alum further augments the immune response and helps maintain antibody titers over time[1][2][3][5]. The approach represents a breakthrough as the first-in-human example of a fully synthetic, homogeneous glycan-protein conjugate vaccine advancing to clinical evaluation.
- Other names
- SF2a-TT15 + AlhydrogelSF2a-TT15 formulated with alumSF-2a-TT15 formulated with alumSF 2a-TT15 formulated with alum
02
Targets
BCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on SF2a-TT15 + alum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SF2a-TT15 + alum.